Cargando…
Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity
Serial circulating tumor DNA (ctDNA) monitoring is emerging as a non-invasive strategy to predict and monitor immune checkpoint blockade (ICB) therapeutic efficacy across cancer types. Yet, limited data exist to show the relationship between ctDNA dynamics and tumor genome and immune microenvironmen...
Autores principales: | Cindy Yang, S. Y., Lien, Scott C., Wang, Ben X., Clouthier, Derek L., Hanna, Youstina, Cirlan, Iulia, Zhu, Kelsey, Bruce, Jeffrey P., El Ghamrasni, Samah, Iafolla, Marco A. J., Oliva, Marc, Hansen, Aaron R., Spreafico, Anna, Bedard, Philippe L., Lheureux, Stephanie, Razak, Albiruni, Speers, Vanessa, Berman, Hal K., Aleshin, Alexey, Haibe-Kains, Benjamin, Brooks, David G., McGaha, Tracy L., Butler, Marcus O., Bratman, Scott V., Ohashi, Pamela S., Siu, Lillian L., Pugh, Trevor J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8390680/ https://www.ncbi.nlm.nih.gov/pubmed/34446728 http://dx.doi.org/10.1038/s41467-021-25432-7 |
Ejemplares similares
-
Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis
por: Iafolla, Marco A J, et al.
Publicado: (2020) -
An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE)
por: Clouthier, Derek L., et al.
Publicado: (2019) -
Predicting response and toxicity to PD-1 inhibition using serum autoantibodies identified from immuno-mass spectrometry
por: Music, Milena, et al.
Publicado: (2020) -
Centromeric cohesion failure invokes a conserved choreography of chromosomal mis-segregations in pancreatic neuroendocrine tumor
por: Quevedo, Rene, et al.
Publicado: (2020) -
Increase in serum choline levels predicts for improved progression-free survival (PFS) in patients with advanced cancers receiving pembrolizumab
por: Watson, Geoffrey Alan, et al.
Publicado: (2022)